Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/1996
10/03/1996WO1996030406A1 Human g-protein coupled receptors
10/03/1996WO1996030405A1 Peptides with growth promotion properties
10/03/1996WO1996030404A1 Intracellular signaling proteins and methods of use
10/03/1996WO1996030403A1 Methods of treating disorders of the eye
10/03/1996WO1996030402A1 Nucleotide and protein sequences of lats genes and methods based thereon
10/03/1996WO1996030401A1 Glycopeptide antibiotic derivatives
10/03/1996WO1996030400A1 THE gC1q RECEPTOR, HIV-1 gp120 REGION BINDING THERETO, AND RELATED PEPTIDES AND TARGETING ANTIBODIES
10/03/1996WO1996030399A1 Cyclic peptide nuclei and derivatives thereof
10/03/1996WO1996030397A1 New peptides with immunomodulatory effects
10/03/1996WO1996030396A1 β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS
10/03/1996WO1996030395A2 Cysteine protease inhibitor
10/03/1996WO1996030392A1 Process for the production of combinatorial compound libraries
10/03/1996WO1996030389A1 Compositions for the diagnosis, prevention, and treatment of tumor progression
10/03/1996WO1996030387A1 Novel human cytomegalovirus dna sequences
10/03/1996WO1996030385A1 Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
10/03/1996WO1996030384A1 Single-stranded circular oligonucleotides
10/03/1996WO1996030378A1 Bisphosphonic acid derivatives
10/03/1996WO1996030353A1 Reversible protease inhibitors
10/03/1996WO1996030332A1 O-malonyltyrosyl compounds, o-malonyltyrosyl compound-containing peptides, and uses thereof
10/03/1996WO1996030057A1 Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
10/03/1996WO1996030052A1 Limbic system-associated membrane protein and dna
10/03/1996WO1996030050A1 Gene therapy by secretory gland expression
10/03/1996WO1996030047A1 Immunotargeting of plasminogen activators to the pulmonary endothelium
10/03/1996WO1996030046A1 Vascular endothelial cell growth factor antagonists
10/03/1996WO1996030043A1 Treatment for verotoxin-producing escherichia coli
10/03/1996WO1996030042A2 Methods of treating inflammation and compositions therefor
10/03/1996WO1996030041A1 Protein formulation comprising coagulation factor viii or factor ix in an aqueous solution
10/03/1996WO1996030040A1 Monomeric insulin analog formulations
10/03/1996WO1996030039A1 Method for enhancing the antibody response to specific antigens with interleukin-10
10/03/1996WO1996030038A1 Peptide growth factor having epidermal inducing activity
10/03/1996WO1996030037A1 Method of treating conditions associated with burn injuries
10/03/1996WO1996030036A1 Compounds and compositions for delivering active agents
10/03/1996WO1996030035A1 β-SHEET MIMETICS AND USE THEREOF AS INHIBITORS OF BIOLOGICALLY ACTIVE PEPTIDES OR PROTEINS
10/03/1996WO1996030031A1 Isolated stromal cells and methods of using the same
10/03/1996WO1996030028A2 Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
10/03/1996WO1996030006A1 Nitrosylated blood substitutes
10/03/1996WO1996029999A1 Medicament with angiotensin converting enzyme (ace) inhibitors suitable for transdermal application
10/03/1996WO1996029989A1 Stable protein:phospholipid compositions and methods____________
10/03/1996WO1996029987A1 Reduction of adhesions using controlled delivery of active oxygen inhibitors
10/03/1996WO1996029974A2 Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
10/03/1996WO1996026285A3 Methods and compositions for administering gene therapy vectors
10/03/1996WO1996024348A3 Use of carbazole compounds for the treatment of congestive heart failure
10/03/1996WO1996023884A3 Human peroxisome proliferator activated receptors
10/03/1996WO1996003436A3 EQUINE η-INTERFERON
10/03/1996WO1994004702A3 Improved detection and therapy of lesions with biotin/avidin conjugates
10/03/1996CA2805588A1 Vascular endothelial cell growth factor antagonists
10/03/1996CA2754887A1 Vascular endothelial cell growth factor antagonists
10/03/1996CA2218601A1 Treatment for verotoxin-producing escherichia coli
10/03/1996CA2217009A1 T-cell receptors and their use in therapeutic and diagnostic methods
10/03/1996CA2216878A1 Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
10/03/1996CA2216842A1 Limbic system-associated membrane protein and dna
10/03/1996CA2216806A1 Insulin mimetic and enhancer assay
10/03/1996CA2216755A1 Peptides with growth promotion properties
10/03/1996CA2216702A1 Nucleotide and protein sequences of lats genes and methods based thereon
10/03/1996CA2216651A1 Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
10/03/1996CA2216516A1 Monomeric insulin analog formulations
10/03/1996CA2216445A1 Gene therapy for transplantation and inflammatory or thrombotic conditions
10/03/1996CA2216428A1 Dna molecule relating to suppression of gene expression and novel protein
10/03/1996CA2216292A1 Haemophilus adhesion proteins
10/03/1996CA2216278A1 Transdermally administrable medicament with ace inhibitors
10/03/1996CA2216174A1 Gene expression in mammalian cells
10/03/1996CA2216151A1 Reversible protease inhibitors
10/03/1996CA2216149A1 Gene therapy by secretory gland expression
10/03/1996CA2215968A1 Method for enhancing the antibody response to specific antigens with interleukin-10
10/03/1996CA2215720A1 .beta.-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
10/03/1996CA2215355A1 Antibody, hybridoma and use thereof
10/03/1996CA2215330A1 Methods of treating disorders of the eye
10/03/1996CA2215211A1 Cysteine protease inhibitor
10/03/1996CA2215143A1 Isolated stromal cells and methods of using the same
10/03/1996CA2214988A1 Method of treating inflammation and compositions therefor
10/03/1996CA2214499A1 Gene transfer into the kidney
10/03/1996CA2214451A1 Conditional expression system
10/03/1996CA2191214A1 Apoptosis regulating gene
10/03/1996CA2189656A1 New peptides with immunomodulatory effects
10/02/1996EP0735138A2 Fungal cell wall protein Cly4
10/02/1996EP0735048A1 Monomeric insulin analog formulations
10/02/1996EP0735046A1 Oligonucleotide and carcinostatic agent containing the same as active ingredient
10/02/1996EP0735019A2 Retroviral protease inhibitors
10/02/1996EP0734737A2 Particle delivery of particularly therapeutic powdered agents
10/02/1996EP0734730A1 Use of a CGRP antagonist for the treatment of ocular or eyelid pruritis and disesthesies
10/02/1996EP0734729A1 Use of a CGRP antagonist for the treatment of cutaneous erythema of neurogenic origin and so obtained composition
10/02/1996EP0734728A1 Use of a CGRP antagonist for the treatment of lichens and pruritis and composition so obtained
10/02/1996EP0734725A2 Adjuvants containing colloidal iron compounds
10/02/1996EP0734721A2 Method of incorporating drugs into a polymer component of stents
10/02/1996EP0734529A1 Methods and materials for the detection of staphylococcus aureus
10/02/1996EP0734451A1 ENTEROTOXINS OF $i(SHIGELLA FLEXNERI) 2a
10/02/1996EP0734448A1 Gene therapy for restenosis using an adenoviral vector
10/02/1996EP0734442A1 Diagnosis of metastatic cancer by the mts-1 gene
10/02/1996EP0734439A1 p53-BINDING POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME
10/02/1996EP0734436A1 Inhibition of dna methyltransferase
10/02/1996EP0734396A1 ANALOGUES OF hGH-RH (1-29)NH 2? HAVING ANTAGONISTIC ACTIVITY
10/02/1996EP0734395A1 Interleukin-1 receptor antagonist decreases severity of acute pancreatitis
10/02/1996EP0734394A1 Peptide inhibitors of cxc intercrine molecules
10/02/1996EP0734391A1 Pna-dna-pna chimeric macromolecules
10/02/1996EP0734266A1 Controlled superovulation method for female cattle undergoing prolonged anoestrus, anoestruation method and superovulation kit
10/02/1996EP0734265A1 Il-6 therapy
10/02/1996EP0734264A1 Compositions that specifically bind to colorectal cancer cells and methods of using the same
10/02/1996EP0734263A1 ALPHAvBETA3 INTEGRIN AS A PREDICTOR OF ENDOMETRIOSIS
10/02/1996EP0734251A1 Method of transmitting a biologically active material to a cell
10/02/1996EP0734248A1 Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent
1 ... 2763 2764 2765 2766 2767 2768 2769 2770 2771 2772 2773 2774 2775 2776 2777 2778 2779 2780 2781 2782 2783 ... 3163